store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Lanabecestat (AZD3293) 是一种具有高效性和高渗透性、口服活性且可穿过血脑屏障的 BACE1 抑制剂(Ki:0.4 nM),Lanabecestat 可用于研究像阿尔茨海默症类的神经系统疾病。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
2 mg | ¥ 997 | 现货 | ||
5 mg | ¥ 1,830 | 现货 | ||
25 mg | ¥ 6,910 | 8-10周 | ||
50 mg | ¥ 9,170 | 8-10周 | ||
100 mg | ¥ 14,500 | 8-10周 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,970 | 现货 |
产品描述 | Lanabecestat (AZD3293) is a highly potent and highly permeable, orally active BACE1 inhibitor (Ki: 0.4 nM) that crosses the blood-brain barrier, Lanabecestat can be used for the study of neurological diseases like Alzheimer's disease. |
靶点活性 | BACE1:0.4 nM (cell free), BACE1:0.4 nM |
体外活性 | Lanabecestat 差异性地改变了 5xFAD 和 APP KI小鼠的小胶质细胞蛋白水平[1]。 |
体内活性 | Lanabecestat 治疗(1 mg/kg;口服灌胃;每天一次;持续 3 周)能在 4-AP 细胞发生模型中增加了 Bace1-null 小鼠的爆发频率[1]。 |
细胞实验 | Cells are incubated with different Lanabecestat concentrations for 5 to 16?h, and the release of sAβPPβ, Aβ1-40, Aβ1-42, or sAβPPα into the medium is analyzed using kits. Cytotoxic effect of Lanabecestat is evaluated in the cell plates using cell proliferation/cytotoxicity kit. |
动物实验 | Female 7- to 14-week-old C57BL/6 mice (n=6 per treatment group and time point) receive a vehicle or Lanabecestat solution at 50, 100, or 200 μmol/kg (20, 41, or 82?mg/kg) as a single dose via oral gavage. Mice and guinea pigs are anesthetized 1.5, 2, 3, 4, 6, 8, 16, 24, or 48?h after the (last) administration of vehicle or drug and are then kept under isoflurane anesthesia. Cerebrospinal fluid (CSF) is aspirated from the cisterna magna, and plasma is isolated from blood collected by cardiac puncture into EDTA tubes. The animals are then sacrificed by decapitation, and the brains are dissected into hemispheres. |
别名 | LY3314814, AZD3293 |
分子量 | 412.53 |
分子式 | C26H28N4O |
CAS No. | 1383982-64-6 |
store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 80 mg/mL (193.92 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.4241 mL | 12.1203 mL | 24.2407 mL | 60.6017 mL |
5 mM | 0.4848 mL | 2.4241 mL | 4.8481 mL | 12.1203 mL | |
10 mM | 0.2424 mL | 1.212 mL | 2.4241 mL | 6.0602 mL | |
20 mM | 0.1212 mL | 0.606 mL | 1.212 mL | 3.0301 mL | |
50 mM | 0.0485 mL | 0.2424 mL | 0.4848 mL | 1.212 mL | |
100 mM | 0.0242 mL | 0.1212 mL | 0.2424 mL | 0.606 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Lanabecestat 1383982-64-6 Neuroscience BACE AZD-3293 LY3314814 AZD 3293 LY-3314814 AZD3293 LY 3314814 Inhibitor inhibitor inhibit